TMO - NYSE
Thermo Fisher Scientific Inc.
$473.95
-1.7%Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotThermo Fisher Scientific Inc. Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Room for improvement: Moderate profitability with opportunities to enhance margins through better cost management or pricing strategy.
Thermo Fisher Scientific Inc. Income Statement
TMO • NYSE
| Thermo Fisher Scientific Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
44.6B | 42.9B | 42.9B | 44.9B | 39.2B | 32.2B | 25.5B | 24.4B | 20.9B | 18.3B | 17B | 16.9B | 13.1B | 12.5B | 11.7B | 10.8B | 10.1B | 10.5B | 9.7B | 3.8B | |
GROSS PROFIT | ||||||||||||||||||||
(27.8B) | (25.2B) | (25.7B) | (25.9B) | (19.6B) | (16.2B) | (14.2B) | (13.4B) | (11.2B) | (9.7B) | (9.1B) | (9B) | (7.5B) | (7.1B) | (6.7B) | (6.1B) | (6B) | (6.3B) | (5.9B) | (2.1B) | |
16.8B | 17.7B | 17.2B | 19B | 19.6B | 16B | 11.3B | 11B | 9.7B | 8.6B | 7.8B | 7.9B | 5.6B | 5.4B | 4.9B | 4.3B | 4.1B | 4.2B | 3.9B | 1.7B | |
OPERATING INCOME | ||||||||||||||||||||
(8.7B) | (10.1B) | (9.7B) | (10.5B) | (9.3B) | (8.1B) | (7.1B) | (7.1B) | (6.4B) | (5.7B) | (5.3B) | (5.5B) | (3.8B) | (3.8B) | (3.4B) | (3B) | (3B) | (3B) | (2.8B) | (1.3B) | |
(7.3B) | (8.7B) | (8.4B) | (9B) | (7.9B) | (6.9B) | (6.1B) | (6B) | (5.4B) | (4.9B) | (4.6B) | (4.8B) | (3.4B) | (3.3B) | (3B) | (2.7B) | (2.7B) | (2.7B) | (2.5B) | (1.1B) | |
(1.4B) | (1.4B) | (1.3B) | (1.5B) | (1.4B) | (1.2B) | (1B) | (967M) | (888M) | (754.8M) | (692.3M) | (691.1M) | (395.5M) | (376.4M) | (340.2M) | (284.4M) | (246.1M) | (249.1M) | (238.7M) | (170.2M) | |
8.1B | 7.7B | 7.4B | 8.5B | 10.3B | 7.9B | 4.3B | 3.9B | 3.3B | 2.9B | 2.5B | 2.3B | 1.8B | 1.6B | 1.5B | 1.3B | 1.1B | 1.3B | 1.1B | 365.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(1.4B) | (1.7B) | (1.5B) | (726M) | (536M) | (553M) | (676M) | (667M) | (592M) | (469.6M) | (414.9M) | (479.9M) | (262.3M) | (241.6M) | (191.8M) | (84.7M) | (118.1M) | (129.9M) | (139.8M) | (51.9M) | |
-426M | -576M | -612M | -454M | -493M | -488M | -452M | -530M | -511M | -421.2M | -384.3M | -432.2M | -234.3M | -216.4M | -165M | -72.3M | -102M | -78.2M | -93.3M | -35.5M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (20M) | (121M) | (110M) | (96.2M) | (85.4M) | (80.6M) | (70.7M) | (66.2M) | (0.0) | (0.0) | (38.9M) | (34.7M) | (40.5M) | (41.3M) | |
-842M | -667M | -1.2B | -862M | -1.5B | -670M | -189M | -610M | -838M | -835M | -558.1M | -261.2M | -479.2M | -359.9M | -348.6M | -176.8M | -190.8M | -116.7M | -184.5M | -155.9M | |
7.3B | 7B | 6.2B | 7.7B | 8.8B | 7.2B | 4.1B | 3.3B | 2.4B | 2B | 1.9B | 2.1B | 1.3B | 1.3B | 1.1B | 1.1B | 927.1M | 1.1B | 881.3M | 209.4M | |
NET INCOME | ||||||||||||||||||||
(547M) | (657M) | (284M) | (703M) | (1.1B) | (850M) | (374M) | (324M) | (201M) | -1.4M | -43.9M | (191.7M) | (40.4M) | (11M) | (109.4M) | (101.6M) | (75.8M) | (160.9M) | (101.7M) | (43.1M) | |
6.7B | 6.3B | 6B | 7B | 7.7B | 6.4B | 3.7B | 2.9B | 2.2B | 2B | 2B | 1.9B | 1.3B | 1.2B | 1.3B | 1B | 850.3M | 994.2M | 761.1M | 168.9M |
SEC Filings
TMO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 01, 2025 | November 24, 2025 | 2025 |
Related Guides
Continue your TMO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.